Aspirin Dosing in Pregnancy

Part of paid clinical trials in New York, New York.

Sponsor
NYU Langone Health
Study ID
NCT07525635
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Preeclampsia Possible

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Aspirin — DRUG
    81mg twice a day (162mg total)

Study Details

The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.

Key Dates

Start date
Apr 27, 2026
Status verified
Apr 2026
Primary completion
Aug 1, 2027
Completion
Feb 20, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: Twice daily dosing of Aspirin
    Participants will take 81mg Aspirin orally, twice daily (162mg total) for 4 weeks and then return to the dosing regimen as prescribed by the discretion of their treating physician.

Primary Outcome Measure

Measures of platelet aggregation assessed by Light Transmission Aggregometry (LTA) [ Time Frame: Baseline, 4 weeks after initiation of aspirin ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
NYU Langone HealthNew YorkNew York10016-

Find similar trials in New York, NY

By research site
NYU Langone Health· New York, NY